Pfizer Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-8.3%projected annual EPS growth
Analyst Coverage
26analysts covering
Monitoring Framework
Key Performance Indicators
Adjusted Diluted Earnings Per Share (EPS) Quarterly0.8Target: 2.80 to 3.00
Full-Year Revenue Guidance Annually14.5BTarget: 59.5 Billion to 62.5 Billion
Watch Items
- CFO Transition and Leadership StabilityTrigger: Interim CFO Cecile Guegan's performance and potential permanent appointment after August 16, 2026Action: Monitor upcoming Q2 2026 earnings call on August 4, 2026, for guidance reaffirmation and strategic updates.
- Obesity and Oncology Pipeline ProgressTrigger: Clinical trial readouts and regulatory milestones for obesity candidates and Vesper-1 Phase 3 enrollmentAction: Track pipeline updates to assess long-term growth potential offsetting patent cliff erosion.
Research as of 2 Sep 2026